{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:20:22Z","timestamp":1774891222572,"version":"3.50.1"},"reference-count":18,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Psoriasis severely affects quality of life, particularly in patients with moderate to severe psoriasis. This study aims to estimate health utility by Psoriasis Area and Severity Index (PASI) response after biologic induction therapy in Chinese patients with moderate to severe psoriasis.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Based on an established mapping algorithm between the Dermatology Life Quality Index and EuroQol 5 Dimension 5 Level utility score, the retrospective Dermatology Life Quality Index total scores before and after biologic induction therapy in 512 patients were converted into health utility scores to assess the associations between PASI response and post-induction utility using a multivariate generalized linear regression model. The constructed regression model was further applied to estimate post-induction utility by PASI response for a representative patient cohort, including 300 moderate to severe psoriasis patients from five tertiary hospitals.\n                    <jats:bold>Results:<\/jats:bold>\n                    When compared with baseline utility, the post-induction utility increased significantly irrespective of PASI response status. The multivariate regression analysis indicated that higher PASI response status was significantly correlated with higher utility score when compared with PASI &lt;50 (coefficient: 0.050\u20130.124, p\u00a0&lt;\u00a00.001). Relative to the baseline utility before treatment (0.653) in the representative patient cohort, the estimated post-induction utility increased by 0.174 for PASI &lt;50, 0.224 for PASI 50\u201374, 0.275 for PASI 75\u201389, 0.280 for PASI 90\u201399 and 0.298 for PASI 100, respectively.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    As the extent of PASI improvement increases in Chinese patients with moderate to severe psoriasis, their health utility values rise significantly. However, the improvement in quality of life above PASI 75 is relatively limited when compared with PASI 75.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0122","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:24:46Z","timestamp":1774279486000},"source":"Crossref","is-referenced-by-count":0,"title":["Health utility by Psoriasis Area and Severity Index response status after biologic induction therapy in Chinese patients with moderate to severe psoriasis"],"prefix":"10.57264","volume":"15","author":[{"given":"Lu","family":"Jian","sequence":"first","affiliation":[{"name":"Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingzhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Hu","sequence":"additional","affiliation":[{"name":"Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfang","family":"Duan","sequence":"additional","affiliation":[{"name":"Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Tan","sequence":"additional","affiliation":[{"name":"Changsha Normin Health Technology Ltd, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendong","family":"Chen","sequence":"additional","affiliation":[{"name":"Changsha Normin Health Technology Ltd, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingfa","family":"Li","sequence":"additional","affiliation":[{"name":"Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehong","family":"Kuang","sequence":"additional","affiliation":[{"name":"Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_9_3_2","first-page":"37","article-title":"Epidemiology and treatment of psoriasis: a Chinese perspective","volume":"4","author":"Pan R","year":"2014","unstructured":"Pan R, Zhang J. Epidemiology and treatment of psoriasis: a Chinese perspective. Psoriasis Targets Ther. 4, 37\u201347 (2014).","journal-title":"Psoriasis Targets Ther."},{"issue":"5","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13555-024-01159-3","article-title":"Unmet needs and treatment preference of systemic treatments for moderate-to-severe psoriasis from the perspectives of patients and dermatologists in China","volume":"14","author":"Kuang Y","year":"2024","unstructured":"Kuang Y, Li Y, Lv C Unmet needs and treatment preference of systemic treatments for moderate-to-severe psoriasis from the perspectives of patients and dermatologists in China. Dermatol. Ther. (Heidelb.) 14(5), 1245\u20131257 (2024).","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"11","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis","volume":"135","author":"Nast A","year":"2015","unstructured":"Nast A, Jacobs A, Rosumeck S, Werner RN. Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: a systematic review and meta-analysis. J. Invest. Dermatol. 135(11), 2641\u20132648 (2015).","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter A","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J. Am. Acad. Dermatol. 82(6), 1445\u20131486 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"675523","DOI":"10.3389\/fpubh.2021.675523","article-title":"Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: a systematic review","volume":"9","author":"Zhou T","year":"2021","unstructured":"Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: a systematic review. Front. Public Health 9, 675523 (2021).","journal-title":"Front. Public Health"},{"issue":"1","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13696998.2016.1219359","article-title":"EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis","volume":"20","author":"Pickard AS","year":"2017","unstructured":"Pickard AS, Gooderham M, Hartz S, Nicolay C. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. J. Med. Econ. 20(1), 19\u201327 (2017).","journal-title":"J. Med. Econ."},{"issue":"3","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000113150","article-title":"Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis","volume":"216","author":"Revicki DA","year":"2008","unstructured":"Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 216(3), 260\u2013270 (2008).","journal-title":"Dermatology"},{"issue":"2","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","article-title":"Quality of life in patients with psoriasis: a systematic literature review","volume":"9","author":"de Korte J","year":"2004","unstructured":"de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J. Investig. Dermatol. Symp. Proc. 9(2), 140\u2013147 (2004).","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"issue":"3","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00403-012-1309-2","article-title":"Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities","volume":"305","author":"Blome C","year":"2013","unstructured":"Blome C, Beikert FC, Rustenbach SJ, Augustin M. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch. Dermatol. Res. 305(3), 197\u2013204 (2013).","journal-title":"Arch. Dermatol. Res."},{"issue":"11","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1007\/s11136-017-1607-4","article-title":"Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression","volume":"26","author":"Ali FM","year":"2017","unstructured":"Ali FM, Kay R, Finlay AY Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Qual. Life Res. 26(11), 3025\u20133034 (2017).","journal-title":"Qual. Life Res."},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0039"},{"issue":"01","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JD9.0000000000000074","article-title":"Guidelines for the diagnosis and treatment of psoriasis in China: 2019 concise edition","volume":"3","author":"Committee of Psoriasis DB, Chinese Medical Association","year":"2020","unstructured":"Committee of Psoriasis DB, Chinese Medical Association. Guidelines for the diagnosis and treatment of psoriasis in China: 2019 concise edition. Int. J. Dermatol. Venereol. 3(01), 14\u201326 (2020).","journal-title":"Int. J. Dermatol. Venereol."},{"issue":"1","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12955-023-02215-w","article-title":"Health-related quality of life in primary care patients: a comparison between EQ-5D-5L utility score and EQ-visual analogue scale","volume":"22","author":"Xu RH","year":"2024","unstructured":"Xu RH, Sun R, Tian L, Cheung AW, Wong EL. Health-related quality of life in primary care patients: a comparison between EQ-5D-5L utility score and EQ-visual analogue scale. Health Qual. Life Outcomes 22(1), 2 (2024).","journal-title":"Health Qual. Life Outcomes"},{"issue":"5","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1159\/000531420","article-title":"Quality of life benefit and clinical predictors of complete skin clearance in psoriasis: a multicenter, prospective, real-world study","volume":"239","author":"Jiang Y","year":"2023","unstructured":"Jiang Y, Li Y, Huang D Quality of life benefit and clinical predictors of complete skin clearance in psoriasis: a multicenter, prospective, real-world study. Dermatology 239(5), 802\u2013810 (2023).","journal-title":"Dermatology"},{"issue":"6","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","article-title":"The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients","volume":"28","author":"Abrouk M","year":"2017","unstructured":"Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J. Dermatolog. Treat. 28(6), 488\u2013491 (2017).","journal-title":"J. Dermatolog. Treat."},{"issue":"3","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jdv.13985","article-title":"Why quality of life measurement is important in dermatology clinical practice: an expert-based opinion statement by the EADV task force on quality of life","volume":"31","author":"Finlay AY","year":"2017","unstructured":"Finlay AY, Salek MS, Abeni D Why quality of life measurement is important in dermatology clinical practice: an expert-based opinion statement by the EADV task force on quality of life. J. Eur. Acad. Dermatol. Venereol. 31(3), 424\u2013431 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"28","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"46381","DOI":"10.18632\/oncotarget.18453","article-title":"Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients","volume":"8","author":"Chen K","year":"2017","unstructured":"Chen K, Wang G, Jin H Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget 8(28), 46381\u201346389 (2017).","journal-title":"Oncotarget"},{"issue":"1","key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.det.2018.07.004","article-title":"Biologics and psoriasis: the beat goes on","volume":"37","author":"Kim HJ","year":"2019","unstructured":"Kim HJ, Lebwohl MG. Biologics and psoriasis: the beat goes on. Dermatol. Clin. 37(1), 29\u201336 (2019).","journal-title":"Dermatol. Clin."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:28:31Z","timestamp":1774888111000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.57264\/cer-2025-0122"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0122","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"e250122"}}